Unusual Neisseria species as a cause of infection in patients taking eculizumab - 01/02/19
, Lucy McNamara b, Peter E. Waldron a, Lynda McCulley a, S. Christopher Jones a, Susan J. Bersoff-Matcha aHighlights |
• | Eculizumab is a monoclonal antibody and a terminal complement inhibitor. |
• | Eculizumab is known to increase risk for meningococcal disease. |
• | We report 7 cases of unusual Neisseria spp. infection in eculizumab recipients. |
• | Any Neisseria spp. may cause invasive infectious disease in eculizumab recipients. |
Summary |
Background |
Non-meningococcal, non-gonococcal Neisseria spp. are typically commensal and rarely cause invasive disease. Eculizumab is a terminal complement inhibitor that increases susceptibility to meningococcal disease, but data on disease caused by typically-commensal Neisseria spp. are lacking. This series describes postmarketing reports of typically-commensal Neisseria spp. disease in patients receiving eculizumab.
Methods |
We searched the FDA Adverse Event Reporting System (FAERS) and medical literature for reports of commensal Neisseria spp. disease in patients receiving eculizumab, from eculizumab U.S. approval (2007) through January 31, 2018.
Results |
We identified seven FAERS reports (including one case also reported in the literature) of non-meningococcal, non-gonococcal Neisseria disease, including N. sicca (mucosa)/subflava (n = 2), N. cinerea (n = 2), N. sicca (mucosa) (n = 1), N. mucosa (n = 1, with concurrent alpha-hemolytic Streptococcus bacteremia), and N. flavescens (subflava) (n = 1). Four cases had sources of patient immunosuppression in addition to eculizumab. Three patients had sepsis (n = 2) or septic shock (n = 1). Five patients were bacteremic. All patients were hospitalized; the infections resolved with antibiotics.
Conclusions |
Our search identified seven cases of disease from typically commensal Neisseria spp. in eculizumab recipients. These findings suggest that any Neisseria spp. identified from a normally sterile site in an eculizumab recipient could represent true infection warranting prompt treatment.
Le texte complet de cet article est disponible en PDF.Keywords : Eculizumab, Bacteremia, Nonpathogenic Neisseria, Neisseria mucosa, Neisseria cinerea, Neisseria subflava
Plan
| The views expressed are those of the authors and do not necessarily represent those of, nor imply endorsement from, the U.S. Food and Drug Administration, the Centers for Disease Control and Prevention, or the U.S. government. |
Vol 78 - N° 2
P. 113-118 - février 2019 Retour au numéro
Article précédent
- Microbiological and clinical characteristics of Acinetobacter baumannii bacteremia: Implications of sequence type for prognosis
- Yu-Chung Chuang, Aristine Cheng, Hsin-Yun Sun, Jann-Tay Wang, Yee-Chun Chen, Wang-Huei Sheng, Shan-Chwen Chang
- Tolerance of MRSA ST239-TW to chlorhexidine-based decolonization: Evidence for keratinocyte invasion as a mechanism of biocide evasion
- Helene Marbach, Gema Vizcay-Barrena, Kaveh Memarzadeh, Jonathan A. Otter, Smriti Pathak, Robert P. Allaker, Richard D. Harvey, Jonathan D. Edgeworth
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?